GRONK got me second place in my fantasy football. He got double or triple the points of all of the other TEs
How can they deny ALS patients who eventually suffocate to death the opportunity.
Nice to be moving up on high volume and no news. I suspect we will get some big news soon.
I don't think a large pharma will agree to partner NSI-189 on limited indications given that it could be used off label. Look at Geron's recent deal with J&J for Imetelstat. J&J has global rights to all cancer indications and Geron gets hefty royalties in return
Not sure why you would think GERN would get royalties from OCAT (ACTC) or Biotime. There was no royalty provision in the transfer of IP to BTX
Darn, sounds like you have some anger management issues. Bankrupted you? Maybe a poor investment strategy by putting too much in a biotech with no revenue and doing it on margin. 163L has never been "on the shelf". They have had probably 8 or more clinical trials. They had 1 partially completed stem cell trial. Imetelstat has been the focus for some time. Sounds like your anger clouds your recollection of events, Happy New Year!!!
Enough with the nonsense hedge fund garbage. This happens every third Thursday of every month.
Please take your meds today. We don't need a repeat performance from you.
I highly doubt it. The only person that probably thinks this has much bearing on CUR's future is the STEM pumper.
I work at a trading firm. It's not a naked short. Short volume means nothing. I can sell 1000 shares short and buy it back at a lower price and my position ends up being zero and I generated 1000 shares of short volume.
"No one talks about good AMD cures, or good cervical spine science on this place. Where is the talk about brilliant cures for all that ails the world?"
These cures will happen with other companies. STEM has been around for 25 years and what have the produced other than their own PRs? Where is the validation? The peer reviewed data? It doesn't exist. They have lost 2 CIRM funding opportunities and will likely never get another. Their AMD trial will be irrelevant with OCAT's peer reviewed data. The spinal cord trial will be a distant second to CUR's. Without extremely positive data from these trials STEM is doomed. Hundreds of millions of dollars wasted.